Stock Scorer

Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Inc. reported revenue of 214M USD for the quarter ending 30 June 2026, up 28.1% from 167M a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 214M +28.1%
Gross Profit Q2 '19 · ending 30 June 2019 23.4M +84.8%
Operating Income Q2 '26 · ending 30 June 2026 -75M —
Net Income Q2 '26 · ending 30 June 2026 -92M —
Cost of Revenue Q2 '19 · ending 30 June 2019 766K +443.3%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -97M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -98M —
Shares Outstanding Q2 '26 · ending 30 June 2026 101.9M +5.8%
EPS Q2 '26 · ending 30 June 2026 -5.83 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 673M-535M-575M-472M
20242024-12-31 560M-536M-569M-421M
20232023-12-31 434M-569M-607M-519M
20222022-12-31 363.3M-648.9M-707.4M-496.6M
20212021-12-31 351.4M-381.7M-454M-411.8M
20202020-12-31 271M-330.1M-186.6M-176.1M
20192019-12-31 103.7M-424.2M-402.7M-370.2M
20182018-12-31 51.5M-371.4M-197.6M-294.6M
20172017-12-31 2.6M-328.9M-302.1M-256.6M
20162016-12-31 133K-248M-245.9M-171.2M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-30214M
Q1 '262026-03-31136M
Q4 '252025-12-31207.3M
Q3 '252025-09-30159.9M
Q2 '252025-06-30167M
Q1 '252025-03-31139M
Q4 '242024-12-31164.6M
Q3 '242024-09-30139.5M
Q2 '242024-06-30147M
Q1 '242024-03-31108.8M
Q4 '232023-12-31127.1M
Q3 '232023-09-3098.1M
Q2 '232023-06-30108.3M
Q1 '232023-03-31100.5M
Q4 '222022-12-31103.3M
Q3 '222022-09-3090.7M
Q2 '222022-06-3089.3M
Q1 '222022-03-3179.9M
Q4 '212021-12-3183.4M
Q3 '212021-09-3081.6M

Gross Profit Quarterly

Revenue minus cost of sales. This filer tags no gross profit of its own..

PeriodEndingGross Profit
Q2 '192019-06-3023.4M
Q1 '192019-03-3117.7M
Q4 '182018-12-3115.8M
Q3 '182018-09-3011.5M
Q2 '182018-06-3012.7M
Q1 '182018-03-3110.5M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-75M
Q1 '262026-03-31-169M
Q4 '252025-12-31-113.3M
Q3 '252025-09-30-170.9M
Q2 '252025-06-30-108M
Q1 '252025-03-31-143M
Q4 '242024-12-31-122.3M
Q3 '242024-09-30-132M
Q2 '242024-06-30-116.4M
Q1 '242024-03-31-165.3M
Q4 '232023-12-31-121.8M
Q3 '232023-09-30-145.1M
Q2 '232023-06-30-148M
Q1 '232023-03-31-154.1M
Q4 '222022-12-31-145.6M
Q3 '222022-09-30-225.1M
Q2 '222022-06-30-141.6M
Q1 '222022-03-31-136.6M
Q4 '212021-12-31-102.6M
Q3 '212021-09-30-89.8M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-92M
Q1 '262026-03-31-185M
Q4 '252025-12-31-128.6M
Q3 '252025-09-30-180.4M
Q2 '252025-06-30-115M
Q1 '252025-03-31-151M
Q4 '242024-12-31-133.2M
Q3 '242024-09-30-133.5M
Q2 '242024-06-30-131.6M
Q1 '242024-03-31-170.7M
Q4 '232023-12-31-123.6M
Q3 '232023-09-30-159.6M
Q2 '232023-06-30-159.8M
Q1 '232023-03-31-164M
Q4 '222022-12-31-151.8M
Q3 '222022-09-30-245.1M
Q2 '222022-06-30-158.2M
Q1 '222022-03-31-152.3M
Q4 '212021-12-31-122.5M
Q3 '212021-09-30-73M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '192019-06-30766K
Q1 '192019-03-31452K
Q4 '182018-12-31507K
Q3 '182018-09-30273K
Q2 '182018-06-30141K
Q1 '182018-03-31225K

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-97M
Q1 '262026-03-31-197M
Q4 '252025-12-31-99.8M
Q3 '252025-09-30-91.2M
Q2 '252025-06-30-109M
Q1 '252025-03-31-166M
Q4 '242024-12-31-79.3M
Q3 '242024-09-30-67M
Q2 '242024-06-30-77M
Q1 '242024-03-31-190.7M
Q4 '232023-12-31-84.1M
Q3 '232023-09-30-117.9M
Q2 '232023-06-30-116.2M
Q1 '232023-03-31-156.9M
Q4 '222022-12-31-90.3M
Q3 '222022-09-30-95.3M
Q2 '222022-06-30-77.3M
Q1 '222022-03-31-117.5M
Q4 '212021-12-31-54.3M
Q3 '212021-09-30-59.6M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-98M
Q1 '262026-03-31-198M
Q4 '252025-12-31-100.8M
Q3 '252025-09-30-92.2M
Q2 '252025-06-30-112M
Q1 '252025-03-31-167M
Q4 '242024-12-31-79.5M
Q3 '242024-09-30-68.6M
Q2 '242024-06-30-79M
Q1 '242024-03-31-193.9M
Q4 '232023-12-31-85.4M
Q3 '232023-09-30-121.6M
Q2 '232023-06-30-130.1M
Q1 '232023-03-31-181.9M
Q4 '222022-12-31-117.3M
Q3 '222022-09-30-121.4M
Q2 '222022-06-30-108.2M
Q1 '222022-03-31-149.7M
Q4 '212021-12-31-70.4M
Q3 '212021-09-30-80.2M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30101.9M
Q1 '262026-03-31100.6M
Q3 '252025-09-3099.8M
Q2 '252025-06-3098.5M
Q1 '252025-03-3196.3M
Q3 '242024-09-3095.5M
Q2 '242024-06-3086.6M
Q1 '242024-03-3184.3M
Q3 '232023-09-3071.7M
Q2 '232023-06-3070.9M
Q1 '232023-03-3170.4M
Q3 '222022-09-3070.1M
Q2 '222022-06-3069.9M
Q1 '222022-03-3169.5M
Q3 '212021-09-3067.9M
Q2 '212021-06-3067.6M
Q2 '202020-06-3061.1M
Q2 '192019-06-3057.5M
Q1 '192019-03-3153.2M
Q1 '182018-03-3149.1M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-5.83
Q1 '262026-03-31-6.10
Q4 '252025-12-31-5.83
Q3 '252025-09-30-5.93
Q2 '252025-06-30-5.52
Q1 '252025-03-31-5.87
Q4 '242024-12-31-6.33
Q3 '242024-09-30-6.39
Q2 '242024-06-30-7.22
Q1 '242024-03-31-7.95
Q4 '232023-12-31-8.25
Q3 '232023-09-30-8.97
Q2 '232023-06-30-10.24
Q1 '232023-03-31-10.25
Q4 '222022-12-31-10.11
Q3 '222022-09-30-9.74
Q2 '222022-06-30-7.32
Q1 '222022-03-31-6.87
Q4 '212021-12-31-6.71
Q3 '212021-09-30-5.29